|
|
||||||||
1 Centre de Recherche de l'Hôpital Sainte-Justine, Department of Pediatrics and Pharmacology, Université de Montréal, Montréal, H3T 1C5; 2 Department of Pharmacology and Therapeutics, McGill University, Montréal, H3G 1Y6; and 3 Theratechnologies, Ville St-Laurent, Quebec, Canada, H4S 2A4
| |
ABSTRACT |
|---|
|
|
|---|
Oxidant stress contributes to the
pathogenesis of hypoxic-ischemic encephalopathies.
Platelet-activating factor (PAF) is generated during oxidant stress. We
studied the vasomotor mode of actions of PAF on periventricular (PV)
microvessels of fetal (
75% of term), newborn (1-3 days), and
adult pigs. PAF constricted PV microvessels from fetal (29.27 ± 2.6%) and newborn (22.14 ± 3.2%) pigs but was ineffective in
adults (<2.5%). Specific [3H]PAF binding was greater in
fetus and newborn than in adults; a concordant developmental
PAF-induced inositol phosphate formation was observed. PAF-induced
vasoconstriction was abrogated by thromboxane A2
(TXA2) synthase and receptor inhibitors, calcium channel
blockers, and by removal of endothelium; vasoconstriction to
TXA2 mimetic U-46619 did not differ with age.
Immunoreactive TXA2 synthase expression and PAF-evoked
TXA2 formation revealed a fetus> newborn>adult profile.
Thus the greater PAF-induced PV microvascular constriction in younger
subjects seems attributable to greater PAF receptor density and mostly
secondary to TXA2 formation from endothelium. The resulting
decrease in blood flow may contribute to the increased vulnerability of
the PV brain regions to oxidant stress-induced injury in immature subjects.
peroxidation; age dependence; thromboxane; ischemia
| |
INTRODUCTION |
|---|
|
|
|---|
OXIDANT STRESS PLAYS a major role in the pathogenesis of various disorders, such as hypoxic-ischemic encephalopathies (38, 42), including periventricular leukomalacia in premature subjects (41, 42). Free radicals can alter brain hemodynamics by causing vasoconstriction (19, 37) and increasing thromboxane A2 (TXA2) formation (1, 26). Although TXA2 has been implicated in peroxidation-induced vasoconstriction (1, 23), the mechanisms of TXA2 production by brain vasculature during oxidant stresses are complex and not fully understood.
Oxidation leads to the activation of a number of pathways and the formation of various factors. An early and important event following peroxidation is the activation of phospholipase A2 (3, 7), which leads to the synthesis of agents with major vascular actions, including platelet-activating factor (PAF) (30, 35). PAF is a phospholipid with diverse biological functions mediated by a G protein-coupled receptor. The production and release of PAF in the brain have been reported under various pathological conditions, including oxidant stress-induced ischemic injury in newborn (4, 25). PAF is a modulator of vasomotor tone and induces pulmonary, coronary, and cerebral vasoconstriction (5, 10, 22). The mechanism of the vascular action of PAF is controversial, but many investigators have shown that some of its effects might be mediated through the formation of cyclooxygenase products of arachidonic acid metabolism in response to activation of PAF receptors (11, 22). However, the direct effects of PAF on brain intraparenchymal vasculature, implicated in the genesis of periventricular ischemic encephalopathies, remain unknown.
Because oxidant stress-induced encephalopathies are mostly localized to the periventricular region in immature subjects compared with older ones (42), we postulated that the constrictor effects of PAF on the microvessels of the periventricular brain region are more pronounced in immature than older subjects, and in this process we evaluated the effects of PAF on these microvessels as well as the role of TXA2 in these vascular responses.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Tissue preparation.
Animals were used according to a protocol of the Animal Care Committee
of Hôpital Sainte-Justine along with the principles of the Guide
for the Care and Use of Experimental Animals of the Canadian Council on
Animal Care. Brains from fetal [78-90 days gestation (term 114 days)] and adult (6-8 mo old) pigs were obtained from an abattoir
(St-Hélène, Québec, Canada) immediately after exsanguination of sows transported in ice-cold buffer to the
laboratory. Newborn pigs (1-3 days old) were acquired from Fermes
Ménard (L'Ange-Gardien, Québec, Canada). Animals were
anesthetized with halothane (~2.5-5%) and killed with
pentobarbital sodium (120 mg/kg). The brains were removed and placed
immediately in ice-cold Krebs buffer (pH 7.4) of the following
composition (in mM): 120 NaCl, 4.5 KCl, 2.5 CaCl2, 1.0 MgSO4, 27 NaHCO3, 1.0 KH2PO4, and 10 glucose; 1.5 U/ml heparin was
added to the buffer. For biochemical measurements, tissues were frozen
in liquid N2 and stored at
80°C.
Vasomotor response of brain periventricular microvessels. Slices of brain (1-mm thick) exposing the periventricular brain region were prepared as previously described (12, 20) to study relatively undisturbed penetrating microvessels (30-50 µm) reported to contribute significantly to the control of cerebral vascular resistance (17). The brain slices were pinned securely to a wax base of a 20-ml bath containing Krebs buffer (pH 7.4) equilibrated with 95% O2-5% CO2 and maintained at 37°C. The preparations were washed two to three times with fresh buffer and allowed to equilibrate for 45 min before starting the experiment.
Cerebral microvessels were visualized and recorded using a video camera (model CCD72, MTI) mounted on a dissecting microscope (model M-400, Nikon), as reported previously (12, 20). Vascular diameter was measured using a digital image analyzer (Sigma Scan software, Jandel Scientific, Corte Madera, CA) and repeated three times with a variability of <1%. Vascular diameter was recorded before and after topical application of increasing concentrations of test agents (C-PAF, thromboxane mimetic U-46619, and PGF2
) in the presence
and absence of a 20-min pretreatment with the following agents at known
effective concentrations (1, 15, 20): TXA2
synthase inhibitor CGS-12970 (1 µM); TXA2 receptor antagonist L-670596 (0.1 µM); PAF receptor antagonist THG-315 (1 µM); non-voltage-dependent Ca2+ entry and
receptor-mediated Ca2+ channel blocker SK&F-96365
(29) (20 µM); L-type voltage-gated Ca2+
channel blocker nifedipine (5 µM); and N-type voltage-gated
Ca2+ channel blocker
-conotoxin (36) (10 µM). Focus was placed on receptor-operated as well as N- and L-types
voltage-gated Ca2+ channels since endothelial cells are not
excitable and are essentially devoid of voltage-gated Ca2+
channels (18), whereas smooth muscle cells and astrocytes
contain voltage-gated Ca2+ channels, mostly L and N type
(14, 34).
Removal of the endothelium. The endothelium of newborn pig brain microvessels was chemically removed by intracarotid perfusion with 3-[(3-cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propanesulphonate (CHAPS; 5 mg/l for 2 min) (32). After denudation, the vasomotor response of brain periventricular microvessels to C-PAF was studied. The removal of the endothelium was considered successful since the vasodilatory response to substance P (1 µM) (12) was absent while tissues responded normally to endothelium-independent stimulants U-46619 (0.2 µM) and sodium nitroprusside (1 µM).
Preparation of brain microvessel membrane.
Microvessels from fetal, newborn, and adult brain were prepared as
previously described (20, 24). Briefly, periventricular brain region was homogenized, preserving microvascular structure by
homogenizing tissues in 5 mM Tris · HCl buffer
(pH 7.4) containing 1.1 mM acetylsalicylic acid, 0.5 mM EGTA, 1 mM
benzamidine, 0.1 mM phenylmethylsulfonyl fluoride, and 100 µg/ml
soybean trypsin inhibitor with three up-and-down strokes with a tissue
grinder (Wheaton, Teflon type). The homogenate was filtered through a nylon mesh filter (70 µm) and rinsed with the buffer above.
Microvessels were collected from the nylon mesh, resuspended in the
buffer above, rehomogenized with a hand pestle, centrifuged at 1,000 g for 15 min, and refiltered as above. The purified
microvessels were collected, recentrifuged at 100,000 g for
45 min, and the pellet was stored at
80°C until used. The
morphology and purity of microvessels were confirmed by light
microscopy and a 15-fold higher level of
-glutamyl transpeptidase
activity when compared with brain parenchyma, as described previously
(24). The calibers of microvessels used ranged from 20 to
60 µm in diameter.
Microvascular endothelial cell culture. Microvessels were suspended in selective endothelial or smooth muscle growth media (Clonetics). Confluent individual endothelial cells were trypsinized, centrifuged, reseeded in culture flasks, and subcultured; cell viability was verified by trypan blue exclusion and was >90%. Endothelial cells were identified by their cobblestone morphology at confluence, positive reactivity to factor VIII antibody, and negative reactivity to smooth muscle-specific actin and glial fibrillary acidic protein (GFAP) antibodies (Dako, Carpinteria, CA). Confluent cultures of endothelial cells from passages 5-15 were used for experiments.
[3H]PAF binding assay. Membranes were suspended in assay buffer, and proteins were measured by the dye-binding method using BSA as the standard. Saturation binding experiments were performed by incubating 200 µg of brain microvessel membrane proteins for 30 min at 37°C with increasing concentrations of [3H]PAF in the presence or absence of 25 µM unlabeled PAF; specific binding reached equilibrium within 10 to 15 min and remained stable for at least 30 min, as we previously reported (24). Reactions were terminated by the addition of 2.5 ml ice-cold 5 mM Tris · HCl buffer (pH 7.4). The incubates were rapidly filtered through Whatman GF/C glass filter disks and washed three times with 2.5 ml of the same buffer. The radioactivity on the filter disks was counted with a beta counter (Beckman LS6000IC). Receptor densities (maximal binding; Bmax) and dissociation constants (Kd) were determined from the saturation isotherms (24) using a computer program (Prism, GraphPad).
Inositol phosphate assay. PAF receptor activation can be coupled to inositol phosphate production (8, 30). Inositol phosphate formation was determined on periventricular tissues from fetal, newborn, and adult pigs. Tissues were homogenized and incubated with [3H]inositol for 18 h, followed by stimulation with C-PAF (0.1, 1, and 10 µM) for 20 min. Inositol phosphates were then extracted with chloroform/methanol (1:1) and purified with an anionic exchange resin (AG 1-×8) (Bio-Rad, Hercules, CA). The inositol phosphate production was assessed with a scintillation counter.
Thromboxane assay.
Effects of C-PAF on thromboxane formation were studied in fetus,
newborn, and adult pig brain slices stimulated (15 min) with C-PAF at
0.1, 1, and 10 µM; the reaction was terminated with liquid N2. Thromboxane B2 (stable TXA2
metabolite) was assessed on homogenized tissue by radioimmunoassay as
previously described (1, 20). TXB2
concentration was also measured in newborn pig brain slices stimulated
for 15 min with C-PAF (1 µM) in the presence of CGS-12970 (1 µM),
SK&F-96365 (20 µM),
-conotoxin (10 µM), or nifedipine (5 µM).
Immunoblotting of thromboxane synthase. TXA2 synthase immunoreactivity on brain was determined as we previously described for other membrane-bound enzymes (33). Briefly, homogenized tissues from the periventricular regions of all age groups studied were preabsorbed with 50 ml of immunoprecipitin for 30 min and then centrifuged at 12,000 g for 10 min to remove the immunoprecipitin. The supernatant was incubated with porcine TXA2 synthase-specific polyclonal antibodies (Cayman Chemicals) for 1.5 h, and immune complexes were collected by incubation with 50 ml immunoprecipitin for 30 min, followed by centrifugation. Immune precipitates were denatured in SDS buffer, centrifuged at 12,000 g for 15 min to remove the immunoprecipitin, and the samples were loaded on SDS-polyacrylamide gels. The proteins were electrophoretically transferred to nitrocellulose membranes and incubated with TXA2 synthase-specific antibodies. After being washed, the membrane was incubated with horseradish peroxidase-conjugated anti-rabbit IgG antibody followed by several washes. Immunoreactive bands were visualized by enhanced chemiluminescence (Amersham) as recommended by the supplier and analyzed by densitometry.
Ca2+ signals.
Intracellular Ca2+ ([Ca2+]i)
signals were measured using the fluorescent indicator fura 2-AM as we
have reported (20). For this purpose, confluent
endothelial cells of newborn pigs were trypsinized in a solution
containing 0.05% trypsin and 0.02% EDTA for 2 min, then 5 ml of HBSS
was added. Cells were centrifuged at 250 g for 10 min and
resuspended in a buffer containing (in mmol/l) 20 HEPES, 10 D-glucose, 4.6 KCl, 118 NaCl, and 0.5 CaCl2, as
well as 1% fetal bovine serum. Cell viability was determined by trypan
blue exclusion and was >90%. Fura 2-AM (2 µmol/l) and 0.2%
Pluronic F-127 were added to cell suspensions, which were incubated at 37°C for 30 min. The loaded cells were then washed twice and
resuspended in HBSS with Ca2+ (2.5 mM) and 1% fetal bovine
serum with or without a 15-min pretreatment with SK&F-96365 (20 µM),
nifedipine (5 µM), or
-conotoxin (10 µM), followed by
stimulation with C-PAF (1 µM). The [Ca2+]i
was determined in 2 ml of fura 2-AM-loaded cell suspension (~2 × 106 cells/ml) continuously stirred and measured with a
spectrofluorometer (model LS 50, Perkin-Elmer, Beaconsfield, UK) by
using excitation wavelengths of 340 and 380 nm and emission at 510 nm.
Calibration of the fluorescent signal was determined using 10 mM
ionomycin and 5 mM EGTA plus 0.2% Triton X-100 to obtain a maximal and
minimal fluorescence ratio. The [Ca2+]i was
calculated as reported (16).
Chemicals.
L-670596 and CGS-12970 were generous gifts from Merck-Frosst
(Pointe-Claire, PQ, Canada) and Ciba-Geigy (Summit, NJ), respectively. THG-315 was a gift from Theratechnologies (Saint-Laurent, PQ, Canada).
The following products were purchased: C-PAF and SK&F-96365 (BioMol, Plymouth Meeting, PA); U-46619 and PGF2
(Cayman Chemicals); ATP, EDTA, EGTA, ionomycin, nifedipine, Triton
X-100,
-conotoxin, Tris · HCl, and CHAPS
(Sigma Chemical, St. Louis, MO); fura 2-AM (Calbiochem, La Jolla, CA);
TXB2 radioimmunoassay kits (Amersham, Oakville, ON,
Canada); endothelial, smooth muscle cells (Clonetics); Factor VIII
antibody, smooth muscle-specific actin antibody, and GFAP antibody
(Dako); all other chemicals (Fisher Scientific, Montreal, PQ, Canada).
Statistics. All results are expressed as means ± SE. Results were analyzed using Student's t-test and two-way ANOVA factoring for concentrations and age or treatments. Post-ANOVA comparisons among means were performed using the Tukey-Kramer method. P values <0.05 were considered to be significant.
| |
RESULTS |
|---|
|
|
|---|
Effects of PAF on brain periventricular microvessels.
C-PAF caused concentration-dependent constriction of periventricular
microvessels from fetal and newborn pigs, whereas vasoconstriction of
adult pig microvessels was negligible (Fig.
1A). Emax values for fetus, newborn, and adult were 29.27 ± 2.6, 22.14 ± 3.2, and 2.3 ± 0.8%. The EC50 values of
C-PAF on fetal and newborn pig microvessels were comparable: 25.96 ± 0.9 and 19.95 ± 1.4 nM. In contrast, PGF2
was
more effective on adult than fetal and newborn pig microvessels
(P < 0.05) (Fig. 1B), and U-46619 was
equivalently effective on tissues of all three age groups. Because PAF has been shown to increase the production of vasodilator prostaglandins and nitric oxide (30) in several tissues,
we tested whether there were ontogenic changes in relaxant response to
C-PAF; C-PAF did not elicit vasorelaxation, whereas substance P (1 µM) relaxed brain microvessels of all ages (data not shown).
|
Specific [3H]PAF binding on brain microvessels and
inositol phosphate production.
To explain the difference in the response of fetal, newborn, and adult
brain microvessels to C-PAF, we compared PAF receptor density and the
production of the second messenger inositol phosphate in fetal,
newborn, and adult tissues. Maximum specific binding of
[3H]PAF to brain microvessel membranes was greater in
fetus (Bmax 551.5 ± 36.2 fmol/mg protein) than in
newborn (Bmax 423.1 ± 60.6 fmol/mg protein), which
was three times greater than in adult (Bmax 180.0 ± 37.3 fmol/mg protein) (Fig.
2A). Dissociation constants (Kd, nM) were comparable: 28.61 ± 5.2, 27.27 ± 4.8, and 18.11 ± 4.1, respectively, in fetal,
newborn, and adult tissues. PAF-induced inositol phosphate production
exhibited an age-dependent profile that was greater in fetal than in
newborn and minimally present in adult tissues (Fig. 2B).
|
TXA2-mediated vasoconstriction to PAF.
The vasoconstrictor effects of PAF on the microvessels from fetal and
newborn pigs were almost fully inhibited by TXA2 synthase inhibitor CGS-12970 and TXA2 receptor antagonist L-670596
(Fig. 3, A and B).
The role of TXA2 in PAF-induced constriction was not
studied in adults given the negligible vasoconstriction in this age
group. In addition, PAF-induced constriction was virtually abolished by
endothelial denudation (Fig. 3C) as demonstrated in newborn
tissues. Moreover, TXB2 levels increased dose dependently after stimulation of the fetal and newborn periventricular tissue with
PAF (Fig. 4A). In contrast,
TXB2 levels were only mildly increased by PAF stimulation
in adult tissues (Fig. 4A). A similar developmental pattern
of immunoreactive TXA2 synthase expression was observed
(Fig. 4, B and C). Hence, developmental
differences in PAF-induced constriction appear to depend on ontogenic
differences in TXA2 formation, which seems to be generated
largely by the endothelium.
|
|
Involvement of Ca2+ on PAF-induced
TXA2 formation and vasoconstriction.
Because removal of the endothelium completely abolished the
TXA2-dependent action of C-PAF, endothelial cells must
contribute to the TXA2 formation evoked by C-PAF (Fig.
3C). Because enzyme-catalyzed prostanoid formation is
Ca2+ dependent via phospholipase A2, we
attempted to identify the type of Ca2+ channel involved in
PAF-induced TXA2 generation and vasoconstriction. PAF-induced increase in TXB2 formation in periventricular
tissue of newborn pigs was markedly inhibited by CGS-12970, putative receptor-operated Ca2+ channel blocker SK&F-96365
(29), and by the Ca2+ chelator EGTA, but not
by selective N-type voltage-gated Ca2+ channel blocker
-conotoxin MVIIA (36) or L-type voltage-gated Ca2+ channel blocker nifedipine (Fig.
5A); similar inhibition of
PAF-induced increase in TXB2 formation was observed in the
fetus when we tested SK&F-96365 in contrast to
-conotoxin MVIIA (not
shown). Accordingly, vasoconstriction to C-PAF was also nearly
abolished by SK&F-96365 but was unaffected by
-conotoxin MVIIA in
young animals (Fig. 5C). Vasoconstriction to C-PAF and
TXA2 mimetic U-46619 was inhibited by nifedipine (Fig.
5C).
|
-conotoxin
(Fig. 5B). In contrast, C-PAF did not affect
Ca2+ transients in smooth muscle cells. On the other hand,
TXA2 mimetic U-46619 (1 µM) induced Ca2+
transients in smooth muscle cells, which were inhibited by nifedipine (5 µM), but not by SK&F-96365 (20 µM) (data not shown).
| |
DISCUSSION |
|---|
|
|
|---|
PAF is an important phospholipid with diverse physiological and pathological roles in vivo, including effects on circulation (5, 22, 30). Due to its potent actions on blood vessels, PAF might be a putative mediator in ischemic brain injury (25, 26). Little is known about the effects of PAF on brain intraparenchymal microvessels during development. The present study reveals that PAF causes greater constriction of fetus and newborn periventricular microvessels compared with those of adult animals as a result of a higher density of PAF receptor and greater thromboxane generation, principally of endothelial origin, via activation of receptor-operated Ca2+ channels.
PAF exerts its effects by interacting with a specific PAF receptor
(30). Depending on the species and tissues, PAF causes constriction or dilation according to different coupling mechanisms (5, 22, 26). For instance, PAF is a potent constrictor of
cerebral arterioles in newborn pigs (5) and produces
vasodilatation in mesenteric circulation in dogs (30). In
some tissues (e.g., coronary and cerebral vessels), vasoconstriction
evoked by PAF is partly mediated by TXA2 (22,
26). In the present study, effects of PAF on periventricular
microvasculature are also mediated via TXA2, which is
released from endothelial cells (Figs. 3 and 4A). This
inference is based on the following observations: 1) PAF
stimulates calcium-dependent thromboxane production (Fig. 5,
A and B); 2) periventricular
vasoconstriction to PAF is thromboxane dependent (Fig. 3, A
and B); 3) PAF-induced Ca2+ signals,
thromboxane formation, and vasoconstriction are abrogated by
non-voltage-gated calcium channel blocker SK&F-96365, consistent with
absence of voltage-gated calcium channels in endothelium (40); 4) removal of endothelium abolishes
effects of PAF as seen with TXA2 synthase and receptor
blockers (Fig. 3A); and 5) PAF-induced
Ca2+ transients and thromboxane formation were not
inhibited by selective N-type voltage-gated Ca2+ channel
blocker
-conotoxin MVIIA (36) or L-type voltage-gated Ca2+ channel blocker nifedipine (Fig. 5, A and
B), suggesting that perivascular astrocytes that contain N-
and L-type voltage-gated Ca2+ channels (34,
43) are not contributors to the TXA2 formation (20). Accordingly, the efficacy of nifedipine in
PAF-evoked vasoconstriction, but not thromboxane formation, concurs
with the action of PAF-generated thromboxane on L-type voltage-gated Ca2+ channels in smooth muscle (21). Taken
together, these data suggest that PAF increases the influx of calcium
through receptor-operated channels in endothelial cells, and this, in
turn, enhances the formation of thromboxane.
An important observation in this study is the greater constriction
evoked by PAF in the fetus compared with the newborn, which is markedly
larger than that in adult pigs (Fig. 1A); results in the
adult pig are in agreement with the unresponsiveness of mature rats
(13). These findings are of interest because the constrictor responses to a number of agents, such as adrenergic agonists, serotonin, angiotensin, and prostaglandin F2
(Fig. 1B), are often reduced on the blood vessels of younger
subjects compared with those of adult animals (2, 9, 39).
Specific binding of [3H]PAF to brain microvessel
membranes revealed a greater density of PAF receptor in younger than
adult animals (Fig. 2A); mechanisms for this developmental
change remain to be clarified. However, simply a lower density of PAF
receptor in adults could not per se explain the lack of
vasoconstriction to PAF (Fig. 1A). On the other hand, the
virtual absence of PAF-induced thromboxane formation due to diminished
thromboxane synthase protein expression and associated inositol
phosphate production in mature animals is consistent with the vasomotor
response to PAF (Figs. 2 and 4), whereas effects of thromboxane seem
preserved throughout development (Fig. 1C), as previously
reported (20). Hence, developmental changes in PAF-induced
brain microvascular constriction seem partly dependent on ontogenic
differences in PAF receptor density, but maybe mostly due to the
greater thromboxane synthase expression observed in younger subjects
(Fig. 4B). The reason for increased expression of
TXA2 synthase in the periventricular brain region of
immature subjects is not clear. However, its role in the
migration of astrocytes from the germinal matrix in the
periventricular region to others in the developing brain has been
proposed (27). We speculate that the markedly greater
PAF-induced brain microvascular constriction in the younger subjects
may contribute to the hemodynamic compromise and periventricular brain
injury observed in premature neonates exposed to oxidant stress. PAF
antagonists, thromboxane synthase inhibitor, and/or receptor blockers
may attenuate the deleterious effects of oxidant stress (4, 25,
28).
| |
ACKNOWLEDGEMENTS |
|---|
We thank H. Fernandez for technical assistance.
| |
FOOTNOTES |
|---|
This work was supported by grants from the Canadian Institutes of Health Research, the March of Dimes Birth Defects Foundation, the Heart and Stroke Foundation of Quebec, and the Fonds de la Recherche en Santé du Québec. D. Checchin, C. Quiniou, and S. Brault are recipients, respectively, of studentships from the National Science and Engineering Research Council of Canada, the Heart and Stroke Foundation of Canada, and the Research Center of Hôpital Sainte-Justine. A. M. Marrache, S. G. Bernier, F. Gobeil Jr., and S. Chemtob are recipients, respectively, of studentship, fellowship, and scientist awards from the Canadian Institutes of Health Research. S. Chemtob also holds a Canada Research Chair.
Address for reprint requests and other correspondence: S. Chemtob, Research Center, Hôpital Sainte-Justine, Dept. of Pediatrics and Pharmacology, 3175 Côte Sainte-Catherine, Montréal, Québec, Canada, H3T 1C5 (E-mail: sylvain.chemtob{at}umontreal.ca).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
10.1152/ajpregu.00633.2002
Received 11 October 2002; accepted in final form 18 December 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Abran, D,
Varma DR,
and
Chemtob S.
Increased thromboxane-mediated contractions of retinal vessels of newborn pigs to peroxides.
Am J Physiol Heart Circ Physiol
268:
H628-H632,
1995
2.
Abran, D,
Varma DR,
Li DY,
and
Chemtob S.
Reduced responses of retinal vessels of the newborn pig to prostaglandins but not to thromboxane.
Can J Physiol Pharmacol
72:
168-173,
1994[ISI][Medline].
3.
Akiba, S,
Nagatomo R,
Hayama M,
and
Sato T.
Stimulation of cytosolic phospholipase A2-catalyzed arachidonic acid liberation by low dose tert-butyl hydroperoxide without an influence on the enzyme activity in rabbit platelets.
Biochem Mol Biol Int
43:
799-806,
1997[ISI][Medline].
4.
Akisu, M,
Kultursay N,
Coker I,
and
Huseyinov A.
Platelet-activating factor is an important mediator in hypoxic ischemic brain injury in the newborn rat. Flunarizine and Ginkgo biloba extract reduce PAF concentration in the brain.
Biol Neonate
74:
439-444,
1998[ISI][Medline].
5.
Armstead, WM,
Pourcyrous M,
Mirro R,
Leffler CW,
and
Busija DW.
Platelet activating factor: a potent constrictor of cerebral arterioles in newborn pigs.
Circ Res
62:
1-7,
1988
6.
Blank, ML,
Lee T,
Fitzgerald V,
and
Snyder F.
A specific acetylhydrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid).
J Biol Chem
256:
175-178,
1981
7.
Bonventre, JV,
Huang Z,
Taheri MR,
O'Leary E,
Li E,
Moskowitz MA,
and
Sapirstein A.
Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2.
Nature
390:
622-625,
1997[Medline].
8.
Chao, W,
and
Olson MS.
Platelet-activating factor: receptors and signal transduction.
Biochem J
292:
617-629,
1993[ISI][Medline].
9.
Chemtob, S,
Guest I,
Potvin W,
and
Varma DR.
Ontogeny of responses of rabbit aorta to atrial natriuretic factor and isoproterenol.
Dev Pharmacol Ther
16:
108-115,
1991[ISI][Medline].
10.
Clavijo, LC,
Carter MB,
Matheson PJ,
Wills-Frank LA,
Wilson MA,
Wead WB,
and
Garrison RN.
Platelet-activating factor and bacteremia-induced pulmonary hypertension.
J Surg Res
88:
173-180,
2000[ISI][Medline].
11.
Dillon, PK,
Ritter AB,
and
Duran WN.
Vasoconstrictor effects of platelet-activating factor in the hamster cheek pouch microcirculation: dose-related relations and pathways of action.
Circ Res
62:
722-731,
1988
12.
Dumont, I,
Hou X,
Hardy P,
Peri KG,
Beauchamp M,
Najarian T,
Molotchnikoff S,
Varma DR,
and
Chemtob S.
Developmental regulation of endothelial nitric oxide synthase in cerebral vessels of newborn pig by prostaglandin E2.
J Pharmacol Exp Ther
291:
627-633,
1999
13.
Edwards, RM,
Trizna W,
and
Feuerstein G.
Platelet-activating factor (PAF) has no direct effect on rat intracerebral arterioles in vitro.
J Lipid Mediators
3:
161-165,
1991[ISI][Medline].
14.
Fern, R.
Intracellular calcium and cell death during ischemia in neonatal rat white matter astrocytes in situ.
J Neurosci
18:
7232-7243,
1998
15.
Fox, JA.
Novel omega-conopeptides reduced field potential amplitudes in the rat hippocampal slice.
Neurosci Lett
165:
157-160,
1994[ISI][Medline].
16.
Grynkiewicz, G,
Poenie M,
and
Tsien RY.
A new generation of Ca2+ indicators with greatly improved fluorescence properties.
J Biol Chem
260:
3440-3450,
1985
17.
Harper, SL,
Bohlen HG,
and
Rubin MJ.
Arterial and microvascular contributions to cerebral cortical autoregulation in rats.
Am J Physiol Heart Circ Physiol
246:
H17-H24,
1984
18.
Himmel, HM,
Whorton AR,
and
Strauss HC.
Intracellular calcium, currents, and stimulus-response coupling in endothelial cells.
Hypertension
21:
112-127,
1993
19.
Hoffman, SW,
Moore S,
and
Ellis EF.
Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles.
Stroke
28:
844-849,
1997
20.
Hou, X,
Gobeil F, Jr,
Peri K,
Speranza G,
Marrache AM,
Lachapelle P,
Roberts J, II,
Varma DR,
and
Chemtob S.
Augmented vasoconstriction and thromboxane formation by 15-F(2t)-isoprostane (8-iso-prostaglandin F2
) in immature pig periventricular brain microvessels.
Stroke
31:
516-524,
2000
21.
Hughes, AD.
Calcium channels in vascular smooth muscle cells.
J Vasc Res
32:
353-370,
1995[ISI][Medline].
22.
Kinn, JW,
and
Bache RJ.
Effect of platelet activation on coronary collateral blood flow.
Circulation
98:
1431-1437,
1998
23.
Leffler, CW,
Busija DW,
Armstead WM,
and
Mirro R.
H2O2 effects on cerebral prostanoids and pial arteriolar diameter in piglets.
Am J Physiol Heart Circ Physiol
258:
H1382-H1387,
1990
24.
Li, DY,
Varma DR,
and
Chemtob S.
Ontogenic increase in PGE2 and PGF2
receptor density in brain microvessels of pigs.
Br J Pharmacol
112:
59-64,
1994[ISI][Medline].
25.
Liu, XH,
Eun BL,
Silverstein FS,
and
Barks JD.
The platelet-activating factor antagonist BN 52021 attenuates hypoxic-ischemic brain injury in the immature rat.
Pediatr Res
40:
797-803,
1996[ISI][Medline].
26.
Matsuo, Y,
Kihara T,
Ikeda M,
Ninomiya M,
Onodera H,
and
Kogure K.
Role of platelet-activating factor and thromboxane A2 in radical production during ischemia and reperfusion of the rat brain.
Brain Res
709:
296-302,
1996[ISI][Medline].
27.
McDonough, W,
Tran N,
Giese A,
Norman SA,
and
Berens ME.
Altered gene expression in human astrocytoma cells selected for migration. I. Thromboxane synthase.
J Neuropathol Exp Neurol
57:
449-455,
1998[ISI][Medline].
28.
Ment, LR,
Stewart WB,
Petroff OA,
and
Duncan CC.
Thromboxane synthesis inhibitor in a beagle pup model of perinatal asphyxia.
Stroke
20:
809-814,
1989
29.
Merritt, JE,
Armstrong WP,
Benham CD,
Hallam TJ,
Jacob R,
Jaxa-Chamiec A,
Leigh BK,
McCarthy SA,
Moores KE,
and
Rink TJ.
SK&F 96365, a novel inhibitor of receptor-mediated calcium entry.
Biochem J
271:
515-522,
1990[ISI][Medline].
30.
Montrucchio, G,
Alloatti G,
and
Camussi G.
Role of platelet-activating factor in cardiovascular pathophysiology.
Physiol Rev
80:
1669-1699,
2000
31.
Murphy, S,
Pearce B,
Jeremy J,
and
Dandona P.
Astrocytes as eicosanoid-producing cells.
Glia
1:
241-245,
1988[ISI][Medline].
32.
Okazaki, K,
Endou M,
and
Okumura F.
1998 Involvement of barium-sensitive K+ channels in endothelium-dependent vasodilation produced by hypercapnia in rat mesenteric vascular beds.
Br J Pharmacol
125:
168-174,
1998[ISI][Medline].
33.
Peri, K,
Hardy P,
Li DY,
Varma DR,
and
Chemtob S.
Prostaglandin G/H synthase-2 is a major contributor of brain prostaglandins in the newborn.
J Biol Chem
270:
24615-24620,
1995
34.
Porter, JT,
and
McCarthy KD.
Hippocampal astrocytes in situ respond to glutamate released from synaptic terminals.
J Neurosci
16:
5073-5081,
1996
35.
Predescu, D,
Ihida K,
Predescu S,
and
Palade GE.
The vascular distribution of the platelet-activating factor receptor.
Eur J Cell Biol
69:
86-98,
1996[ISI][Medline].
36.
Rivier, J,
Galyean R,
Gray WR,
Azimi-Zonooz A,
McIntosh JM,
Cruz LJ,
and
Olivera BM.
Neuronal calcium channel inhibitors. Synthesis of omega-conotoxin GVIA and effects on 45Ca uptake by synaptosomes.
J Biol Chem
262:
1194-1198,
1987
37.
Sano, K,
Asano T,
Tanishima T,
and
Sasaki T.
Lipid peroxidation as a cause of cerebral vasospasm.
Neurol Res
2:
253-272,
1980[Medline].
38.
Sullivan, JL.
Iron, plasma antioxidants, and the oxygen redical disease of prematurity.
Am J Dis Child
142:
1341-1344,
1988[Medline].
39.
Toda, N,
and
Hayashi S.
Age-dependent alteration in the response of isolated rabbit basilar arteries to vasoactive agents.
J Pharmacol Exp Ther
211:
716-721,
1979
40.
Tran, QK,
Ohashi K,
and
Watanabe H.
Calcium signalling in endothelial cells.
Cardiovasc Res
48:
13-22,
2000
41.
Vannucci, RC,
and
Perlman JM.
Interventions for perinatal hypoxic-ischemic encephalopathy.
Pediatrics
100:
1004-1014,
1997
42.
Volpe, JJ.
Brain injury in the premature infant: overview of clinical aspects, neuropathology, and pathogenesis.
Semin Pediatr Neurol
5:
135-151,
1998[Medline].
43.
Westenbroek, RE,
Bausch SB,
Lin RC,
Franck JE,
Noebels JL,
and
Catterall WA.
Upregulation of L-type Ca2+ channels in reactive astrocytes after brain injury, hypomyelination, and ischemia.
J Neurosci
18:
2321-2334,
1998
This article has been cited by other articles:
![]() |
M. Ahn, D. Beacham, R. E. Westenbroek, T. Scheuer, and W. A. Catterall Regulation of NaV1.2 Channels by Brain-Derived Neurotrophic Factor, TrkB, and Associated Fyn Kinase J. Neurosci., October 24, 2007; 27(43): 11533 - 11542. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |